Pathstone Holdings’s Novartis NVS Stock Holding History

Pathstone Holdings’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.1M	Buy	153,797 +16,900	+12%	+$2.53M	0.07%	185
2026 Q1	$20.9M	Buy	136,897 +18,106	+15%	+$2.78M	0.08%	179
2025 Q4	$16.4M	Buy	118,791 +11,707	+11%	+$1.53M	0.06%	212
2025 Q3	$13.7M	Buy	107,084 +4,060	+4%	+$495K	0.05%	246
2025 Q2	$12.5M	Sell	103,024 -26,459	-20%	-$2.98M	0.05%	261
2025 Q1	$14.6M	Buy	129,483 +27,105	+26%	+$2.89M	0.06%	236
2024 Q4	$9.96M	Sell	102,378 -772	-0.7%	-$82.3K	0.04%	314
2024 Q3	$11.9M	Sell	103,150 -32,123	-24%	-$3.64M	0.05%	270
2024 Q2	$14.4M	Sell	135,273 -5,839	-4%	-$586K	0.07%	212
2024 Q1	$13.7M	Buy	141,112 +43,549	+45%	+$4.47M	0.06%	224
2023 Q4	$9.85M	Buy	+97,563	New	+$9.42M	0.05%	261

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Pathstone Holdings's NVS Position: Q2 2026 in Review

Pathstone Holdings increased its Novartis (NVS) stake by 12% in Q2 2026, buying an estimated $2.53M and bringing the position to 153,797 shares worth $24.1M. The position accounts for 0.07% of the portfolio, ranked #185.

Pathstone Holdings first reported a position in NVS in Q4 2023 and has held it in 11 quarters since. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Pathstone Holdings held 153,797 shares of Novartis worth $24.1M as of Q2 2026.
Pathstone Holdings bought 16,900 Novartis shares in Q2 2026, an estimated $2.53M.
Novartis made up 0.07% of Pathstone Holdings's portfolio in Q2 2026, its #185 holding.
Pathstone Holdings first reported a position in Novartis in Q4 2023 and has held it in 11 quarters since.
1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.